Peritoneal Carcinomatosis clinical trials at UC Cancer
1 research study open to eligible people
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
open to eligible people ages 18-75
This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.
at UC Irvine
Our lead scientists for Peritoneal Carcinomatosis research studies include Maheswari Senthil, MD.